Shionogi Study for COVID-19 (Oral Medication)
Shionogi Study for COVID-19
This study, called the ACTIV-2d (SCORPIO-HR) study, is a global Phase 3 multicenter study evaluating the safety and efficacy of the COVID-19-antiviral agent S-217622 to reduce the duration of COVID-19 symptoms. The study drug is a 3CL protease inhibitor as a once-daily oral treatment for low-risk, non-hospitalized adults with COVID-19 within five days of symptom onset.
If you join this study, you will be compensated $100 per visit (6 in-person visits required), have access to travel reimbursement and/or coordination, and receive either oral study drug or placebo. The study lasts 24 weeks and participating patients will be asked to record symptoms for 29 days in an electronic diary.
What is the type of clinical trial being conducted?
This study is a randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19. Participants will have a 50-50 chance (like tossing a coin) of being assigned to the “active” study drug or placebo.
Who can take part in the study?
You may be able to join the study if you:
- Are 18 or older
- Have low risk of progression to severe COVID-19
- Have tested positive for COVID-19 within the past 5 days
- Have had symptoms for 5 days or less
- Are not currently hospitalized
- Are able to travel to the study site in Grand Rapids, MI
Interested in taking part in a clinical trial?
If you are interested in taking part in one of our active clinical trials, fill out the form below and one of our team members will reach out to you with more information.
Interested in Other Enrolling Clinical Trials?
All of our studies are regulated by the Food and Drug Administration (FDA). To learn about related studies, click on the link below.